

Life feels good.

Founded
2002

Location
Derio, Bizkaia, Spain

Main Focus
Cardiology, Endocrinology, Hepatology,
Gastroenterology, Internal Medicine,
Nephrology, CNS, Nutrition.

About Rubió Metabolomics
Rubió Metabolomics is a biotech company specialized in the discovery, validation and commercialization of metabolomics-based diagnostics, with a strong focus on liver and metabolic diseases such as MASLD / MASH, obesity and diabetes. Building on more than 20 years of research in the field, the company has developed proprietary platforms that enable the identification of novel biomarkers and the creation of non-invasive tests for early detection, patient stratification and disease monitoring.

Rubió Metabolomics is committed to advancing personalized medicine and supporting clinical research worldwide, providing innovative solutions that improve patient care and accelerate the development of new therapies.

International Alliances and Partnering Strategy

Rubió Metabolomics wants to establish international partnerships for its proprietary diagnostic OWLiver® Test, already commercialized in the US through Cima Sciences, a Rubió Group company, while also offering advanced metabolomics services and complementary solutions such as the Liposcale® test to hospitals, CROs and pharmaceutical companies.

Contact details:
Rubió Metabolomics, S.L.U.
Parque Tecnológico de Bizkaia
Edif. 502, pl.0
48160 Derio, Bizkaia, Spain
Tel.: +34 944 318 540
Mob.: +34 650 146 325
www.rubiometabolomics.com

Contact:
afelis@labrubio.com



**Novel advanced test
for lipoprotein size and concentration for the
assessment of Cardiovascular Risk (CVR)**

General Information

Description

The Liposcale® Test is an advanced lipoprotein test based on Nuclear Magnetic Resonance (NMR), which directly measures the normal lipid profile, in addition to the particle number and size, the cholesterol and triglyceride composition of the main lipoprotein classes and subclasses (VLDL, LDL, HDL).

Liposcale® includes:

- The basic lipid profile composed of total cholesterol, LDL, HDL, non-HDL and triglycerides
- The lipid composition: cholesterol and triglycerides concentration of the main types of lipoproteins (VLDL, IDL, LDL and HDL)
- Average particle size (diameter)
- Concentration of 9 subclasses of LDL, HDL and VLDL lipoproteins

This detailed characterization of the lipoproteins allows a more accurate risk stratification, which, in turn, can lead to more effective prevention and treatment of cardiovascular diseases.

Clinical practice

To properly approach CVR in patients, it is essential to correctly estimate it.

LDL-c can over- or under- estimate CHD risk in special groups such as diabetics, patients with metabolic syndrome, etc.

Lipid lowering therapies based on LDL-P show better outcomes compared to based on LDL-C.

A more accurate approach to evaluate CVR caused by LDL can directly measure LDL-P by NMR.

Registration and Marketing Authorization

- The Liposcale® Test is a Class A in vitro diagnostic medical device (IVDMD) that has been developed and patented complying with Regulation EU 2017/746.
- CPT / PLA Code 0377U (USA).

The Liposcale® Test complies with current regulations.

Deal Design

- We are looking for partners with a relevant sales structure in Cardiology, Endocrinology, Hepatology, Gastroenterology, Internal Medicine, Nephrology, or CNS, particularly those oriented towards clinical practice in hospitals and clinics, to properly promote the Liposcale® Test.
- Deal design consisting of a Licensing Agreement to promote and market the Liposcale® Test, which serum or plasma samples will be processed in a local Central Lab with a NMR homologated by Rubió Metabolomics, S.L.U.
- We are searching for the best Partners to develop trustful, fruitful and long term business partnerships.